Intravitreal injection of triamcinolone: An emerging treatment for diabetic macular edema

Diabetes Care

Volumn 27, Issue 7, 2004, Pages 1794-1797

  Ip, Michael S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE ACETONIDE;

CAPILLARY PERMEABILITY; CATARACT; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; GLAUCOMA; HUMAN; INFLAMMATION; LASER COAGULATION; NONHUMAN; NOTE; RETINA CAPILLARY; RETINA DETACHMENT; RETINA MACULA EDEMA; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ANTI-INFLAMMATORY AGENTS; DIABETIC RETINOPATHY; HUMANS; MACULAR EDEMA, CYSTOID; TRIAMCINOLONE;

EID: 3042836667     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.7.1794     Document Type: Note

References (27)

1. Klein R, Klein B, Moss S, Davis M, DeMets D: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 91:1464-1474, 1984
2. Moss S, Klein R, Klein B: Ten-year incidence of visual loss in a diabetic population. Ophthalmology 101:1061-1070, 1994
3. Moss S, Klein R, Klein B: The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105:998-1003, 1998
4. Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
5. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 352:837-853, 1998
6. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema: ETDRS report number 1. Arch Ophthalmol 103: 1796-1806, 1985
7. Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381-389, 2000
8. Early Treatment Diabetic Retinopathy Study Research Group: Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 98:766-785, 1991
9. Lewis H, Abrams G, Blumenkranz M, Campo R: Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992:753-759, 1992
10. Harbour J, Smiddy W, Flynn HJ, Rubsamen P: Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 121:405-413, 1996
11. Tachi N, Ogina N: Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol 122:258-260, 1996
12. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 46:1473-1480, 1997
13. Antonetti D, Barber A, Hollinger L, Wolpert E, Gardner T: Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden. J Bio Chem 274: 23463-23467, 1999
14. Senger D, Galli S, Dvorak A, Peruzzi C, Harvey V, Dvorak H: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983
15. Nauck M, Karakiulakis G, Perruchoud A, Papakonstantinou E, Roth M: Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Euro J Pharmacol 341:309-315, 1998
16. Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P, Perruchoud AP: Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is down-regulated by corticosteroids. Am J Resp Cell Mol Biol 16:398-406, 1997
17. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920-927, 2002
18. Yoshikawa K, Kotake S, Ichiishi A, Sasamoto Y, Kosaka S, Matsuda H: Posterior sub-Tenon injections of repository cortisteroids in uveitis patients with cystoid macular edema. Jap J Ophthalmol 39: 71-76, 1995
19. Thach A, Dugel P, Flindall R, Sipperley J, Sneed S: A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to typical medications. Ophthalmology 104: 2003-2008, 1997
20. Machemer R, Sugita G, Tano Y: Treatment of intraocular proliferations with intravitreal steroids. Tr Am Ophth Soc 77:177-178, 1979
21. Hida T, Chandler D, Arena J, Machemer R: Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101:190-195, 1986
22. McCuen B, Bressler N, Tano Y, Chandler D, Machemer R: The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 91:785-788, 1981
23. Penfold P, Gyory J, Hunyor A, Billson F: Exudative macular degeneration and intravitreal triamcinplone: a pilot study. Aust N Z J Ophthalmol 23:293-298, 1995
24. Challa J, Gillies M, Penfold P, Gyory J, Hunyor A: Exudative macular degeneration and intravitreal tramcinolone: 18 month follow up. Aust N Z J Ophthalmol 26:277-281, 1998
25. Danis R, Ciulla T, Pratt L, Anliker W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244-250, 2000
26. Jonas J, Sofer A: Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132:425-427, 2001
27. Jonas J, Kreissig I, Sotker A, Degenring R: Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57-61, 2003